Clinical trial · Interventional
Standard Care Alone or With Acupuncture for CIPN in Breast Cancer and Multiple Myeloma
Randomised Clinical Trial of Acupuncture Plus Standard Care Versus Standard Care for Chemotherapy Induced Peripheral Neuropathy (CIPN)
NCT02275403CI-TRIAL-00036847ACUFOCINcompletedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to determine whether the addition of acupuncture to standard treatment reduces the level of chemotherapy induced peripheral neuropathy experienced by patients with breast cancer, multiple myeloma, gastrointestinal cancer or gynaecological cancer during or following treatment with neurotoxic chemotherapy.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
| Gastrointestinal Cancer | Malignant Digestive System Neoplasm | ALIAS | 0.90 |
| Gynaecological Cancer | — | UNRESOLVED | — |
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Acupuncture | Procedure | — | UNRESOLVED |
| Medication taken to manage the symptom burden of CIPN | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Arm A: Standard care plus acupuncture
- description
- Medication taken to manage the symptom burden of CIPN plus acupuncture
- interventionNames
- Procedure: Acupuncture
- Other: Medication taken to manage the symptom burden of CIPN
- type
- ACTIVE_COMPARATOR
- label
- Arm B: Standard care alone
- description
- Medication taken to manage the symptom burden of CIPN
- interventionNames
- Other: Medication taken to manage the symptom burden of CIPN
Primary outcomes (1)
- measure
- Change in Measure Yourself Medical Outcome Profile (MYMOP2) score of the most troubling symptom of CIPN
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with breast cancer, multiple myeloma, gastrointestinal cancer or gynaecological cancer who are receiving or who have received neurotoxic chemotherapy treatment for their condition * The capacity to understand the patient information sheet and the ability to give written informed consent * Willingness and ability to comply with scheduled visits and study procedures, including the self-report QoL questionnaires and patient diaries * Age ≥ 18 years; no upper age limit * CIPN of ≥ Grade II (CTCAE v4.03) * Platelet count of ≥ 30 x 10\*9/L * Neutrophil count of ≥ 0.5 x 10\*9/L * MYMOP2 score of their most troubling CIPN symptom ≥ 3 Exclusion Criteria: * Patients who have previously received acupuncture for neuropathy * Patients who have received acupuncture for any indication, other than neuropathy, within the previous 6 months * Women who are pregnant or breast feeding * Co-morbidity with a bleeding disorder * Patients with an aversion to needles
References
Publications (0)
Data not yet available
No reference posted for this study.